Tackling the cancer stem cells-what challenges do they pose?

Nature Reviews Drug Discovery

Volumn 13, Issue 7, 2014, Pages 497-512

  Pattabiraman, Diwakar R ^a   Weinberg, Robert A ^b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; APRINOCARSEN; CD133 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CTN 0328; CWP 232291; FRESOLIMUMAB; GALUNISERTIB; HERMES ANTIGEN; LGK 974; MEDI 0639; MK 0752; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; OPB 31121; PF 3084014; PRI 724; SONIDEGIB; THY 1 ANTIGEN; TRABEDERSEN; UNCLASSIFIED DRUG; VISMODEGIB; WP 1066; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ARRY 382; BETA CATENIN; GEMCITABINE; INTERLEUKIN 6; PATIDEGIB; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CARCINOMA CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL ISOLATION; CELL SUBPOPULATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA; HEMATOPOIETIC CELL; HUMAN; KIDNEY CARCINOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL NICHE; TUMOR MICROENVIRONMENT; APOPTOSIS; BASAL CELL CARCINOMA; CANCER GROWTH; CELL ADHESION; COLORECTAL CANCER; ENZYME INHIBITION; GENE SILENCING; IMMUNOTHERAPY; METASTASIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; STROMA CELL; THERAPY RESISTANCE;

ANTINEOPLASTIC AGENTS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84903768676     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4253     Document Type: Review

References (255)

1. Valent, P. et al. Cancer stem cell definitions and terminology: The devil is in the details. Nature Rev. Cancer 12, 767-775 (2012
2. Wilson, E B. The Cell in Development and Inheritance (ed. Osborn, H. F.) (The Macmillan Company, 1896
3. Pierce, G. B. & Speers, W. C. Tumors as caricatures of the process of tissue renewal: Prospects for therapy by directing differentiation. Cancer Res. 48, 1996-2004 (1988
4. Carney, D. N., Gazdar, A. F., Bunn, P. A. Jr & Guccion, J. G. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells 1, 149-164 (1982
5. Wiseman, D. H., Greystoke, B. F. & Somervaille, T. C. The variety of leukemic stem cells in myeloid malignancy. Oncogene http://dx.doi.org/10.1038/ onc.2013.269 (2013
6. Vermeulen, L. et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl Acad. Sci. USA 105, 13427-13432 (2008
7. Marusyk, A., Almendro, V. & Polyak, K. Intra-Tumour heterogeneity: A looking glass for cancer?. Nature Rev. Cancer 12, 323-334 (2012
8. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012
9. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011
10. Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-291 (2014
11. Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003
12. Eramo, A. et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504-514 (2008
13. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007
14. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951 (2005
15. Lee, A. et al. Isolation of neural stem cells from the postnatal cerebellum. Nature Neurosci. 8, 723-729 (2005
16. Bussolati, B. et al. Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166, 545-555 (2005
17. am Esch, J. S. et al. Portal application of autologous CD133+ bone marrow cells to the liver: A novel concept to support hepatic regeneration. Stem Cells 23, 463-470 (2005
18. Richardson, G. D. et al. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 117, 3539-3545 (2004
19. Cheung, A. M. et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/ SCID engrafting potential. Leukemia 21, 1423-1430 (2007
20. Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007
21. Carpentino, J. E. et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 69, 8208-8215 (2009
22. Ma, S. et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 6, 1146-1153 (2008
23. Jiang, F. et al. Aldehyde dehydrogenase 1 is a tumor stem cell-Associated marker in lung cancer. Mol. Cancer Res. 7, 330-338 (2009
24. Rasheed, Z. A. et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl Cancer Inst. 102, 340-351 (2010
25. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797-1806 (1996
26. Li, R., Wu, X., Wei, H. & Tian, S. Characterization of side population cells isolated from the gastric cancer cell line SGC 7901. Oncol. Lett. 5, 877-883 (2013
27. Li, X. X. et al. Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev. 22, 554-566 (2013
28. Al Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003
29. Kemper, K., Grandela, C. & Medema, J. P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 1, 387-395 (2010
30. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biol. 12, 468-476 (2010
31. Medema, J. P. Cancer stem cells: The challenges ahead. Nature Cell Biol. 15, 338-344 (2013
32. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442-454 (2002
33. Nieto, M. A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 27, 347-376 (2011
34. Puhr, M. et al. Epithelial-To mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR 200c and miR 205. Am. J. Pathol. 181, 2188-2201 (2012
35. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012
36. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584 (2013
37. Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012
38. De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nature Rev. Cancer 13, 97-110 (2013
39. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008
40. Morel, A. P. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3, e2888 (2008
41. Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015-1028 (2012
42. Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in Development and disease. Cell 139, 871-890 (2009
43. Zavadil, J. & Bottinger, E. P. TGF-β and epithelial-To mesenchymal transitions. Oncogene 24, 5764-5774 (2005
44. Ellenrieder, V. et al. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61, 4222-4228 (2001
45. Bakin, A. V., Rinehart, C., Tomlinson, A. K. & Arteaga, C. L. p38 mitogen-Activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115, 3193-3206 (2002
46. Masszi, A. et al. Integrity of cell-cell contacts is a critical regulator of TGF-β1 induced epithelial-To myofibroblast transition: Role for β-catenin. Am. J. Pathol. 165, 1955-1967 (2004
47. Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L. & Arteaga, C. L. Phosphatidylinositol 3 kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275, 36803-36810 (2000
48. Yook, J. I., Li, X. Y., Ota, I., Fearon, E. R. & Weiss, S. J. Wnt-dependent regulation of the E cadherin repressor snail. J. Biol. Chem. 280, 11740-11748 (2005
49. Yook, J. I. et al. A Wnt-Axin2-GSK3β cascade regulates Snail1 activity in breast cancer cells. Nature Cell Biol. 8, 1398-1406 (2006
50. Scheel, C. et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926-940 (2011
51. Li, H. J., Reinhardt, F., Herschman, H. R. & Weinberg, R. A. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2, 840-855 (2012
52. Liu, S. et al. Hedgehog signaling and Bmi 1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071 (2006
53. Bouras, T. et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3, 429-441 (2008
54. Tam, W. L. et al. Protein kinase Cα is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347-364 (2013
55. Celia-Terrassa, T. et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 122, 1849-1868 (2012
56. Battula, V. L. et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435-1445 (2010
57. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-Throughput screening. Cell 138, 645-659 (2009
58. Kurrey, N. K. et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53 mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27, 2059-2068 (2009
59. Farmer, P. et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Med. 15, 68-74 (2009
60. Moore, N. & Lyle, S. Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. J. Oncol. 2011, 396076 (2011
61. Anjomshoaa, A. et al. Slow proliferation as a biological feature of colorectal cancer metastasis. Br. J. Cancer 101, 822-828 (2009
62. Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594 (2010
63. Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62-73 (2010
64. Feuerhake, F., Sigg, W., Hofter, E. A., Dimpfl, T. & Welsch, U. Immunohistochemical analysis of Bcl 2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. Cell Tissue Res. 299, 47-58 (2000
65. Kondo, T., Setoguchi, T. & Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl Acad. Sci. USA 101, 781-786 (2004
66. Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med. 7, 1028-1034 (2001
67. Brennan, K. R. & Brown, A. M. Wnt proteins in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 9, 119-131 (2004
68. Tan, A. R., Alexe, G. & Reiss, M. Transforming growth factor-β signaling: Emerging stem cell target in metastatic breast cancer?. Breast Cancer Res. Treat. 115, 453-495 (2009
69. Visnyei, K. et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol. Cancer Ther. 10, 1818-1828 (2011
70. Mezencev, R., Wang, L. & McDonald, J. F. Identification of inhibitors of ovarian cancer stem-like cells by high-Throughput screening. J. Ovarian Res. 5, 30 (2012
71. Carmody, L. C. et al. Phenotypic high-Throughput screening elucidates target pathway in breast cancer stem cell-like cells. J. Biomolecular Screen. 17, 1204-1210 (2012
72. Sachlos, E. et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149, 1284-1297 (2012
73. Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950-7955 (2011
74. Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644 (2011
75. Mueller, M. M. & Fusenig, N. E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839-849 (2004
76. Hanahan, D. & Coussens, L. M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012
77. Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 196, 395-406 (2012
78. Liu, S. et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71, 614-624 (2011
79. Jinushi, M. et al. Tumor-Associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl Acad. Sci. USA 108, 12425-12430 (2011
80. Yang, J. et al. Tumor-Associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox 2 signaling pathway. Stem Cells 31, 248-258 (2013
81. Marotta, L. L. et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-2735 (2011
82. Ma, X. et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2, e22647 (2013
83. Lin, L. et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene 28, 961-972 (2009
84. Pinto, D., Gregorieff, A., Begthel, H. & Clevers, H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 17, 1709-1713 (2003
85. Booth, C., Brady, G. & Potten, C. S. Crowd control in the crypt. Nature Med. 8, 1360-1361 (2002
86. Birnbaum, T. et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J. Neurooncol. 83, 241-247 (2007
87. Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740 (2001
88. Green, C. E. et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS ONE 4, e6713 (2009
89. Sica, A., Allavena, P. & Mantovani, A. Cancer related inflammation: The macrophage connection. Cancer Lett. 267, 204-215 (2008
90. MacDonald, K. P. et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- And tumor-Associated macrophages but does not inhibit inflammation. Blood 116, 3955-3963 (2010
91. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011
92. Vo, N. & Goodman, R. H. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 276, 13505-13508 (2001
93. Emami, K. H. et al. A small molecule inhibitor of β-catenin/CREB- binding protein transcription [corrected]. Proc. Natl Acad. Sci. USA 101, 12682-12687 (2004
94. Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem. Biol. 5, 100-107 (2009
95. Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224-20229 (2013
96. Rosenbluh, J. et al. β-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473 (2012
97. Anastas, J. N. & Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nature Rev. Cancer 13, 11-26 (2013
98. Katz, L. H. et al. Targeting TGF-β signaling in cancer. Expert Opin. Ther. Targets 17, 743-760 (2013
99. Tremblay, M. R. et al. Discovery of a potent and orally active Hedgehog pathway antagonist (IPI 926).J. Med. Chem. 52, 4400-4418 (2009
100. Jimeno, A. et al. Phase I study of the Hedgehog pathway inhibitor IPI 926 in adult patients with solid tumors. Clin. Cancer Res. 19, 2766-2774 (2013
101. Graham, R. A. et al. Pharmacokinetics of Hedgehog pathway inhibitor vismodegib (GDC 0449) in patients with locally advanced or metastatic solid tumors: The role of α 1 acid glycoprotein binding. Clin. Cancer Res. 17, 2512-2520 (2011
102. LoRusso, P. M. et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC 0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17, 2502-2511 (2011
103. Krop, I. et al. Phase I pharmacologic and pharmacodynamic study of the γ secretase (Notch) inhibitor MK 0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30, 2307-2313 (2012
104. Ridgway, J. et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087 (2006
105. Hoey, T. et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177 (2009
106. Warrell, R. P. Jr., de The, H., Wang, Z. Y. & Degos, L. Acute promyelocytic leukemia. N. Engl. J. Med. 329, 177-189 (1993
107. Carey, J. O., Posekany, K. J., deVente, J. E., Pettit, G. R. & Ways, D. K. Phorbol ester-stimulated phosphorylation of PU.1: Association with leukemic cell growth inhibition. Blood 87, 4316-4324 (1996
108. Wu, H. et al. Reduction in lactate accumulation correlates with differentiation-induced terminal cell division of leukemia cells. Differentiation 48, 51-58 (1991
109. Arcangeli, A. et al. Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential. Proc. Natl Acad. Sci. USA 90, 5858-5862 (1993
110. Olsson, I., Gullberg, U., Ivhed, I. & Nilsson, K. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1α, 25 dihydroxycholecalciferol. Cancer Res. 43, 5862-5867 (1983
111. Munster, P. N. et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61, 8492-8497 (2001
112. Uchida, H., Maruyama, T., Nagashima, T., Asada, H. & Yoshimura, Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up regulation of glycodelin. Endocrinology 146, 5365-5373 (2005
113. Momparler, R. L. Epigenetic therapy of cancer with 5 aza 2Ŷ deoxycytidine (decitabine). Semin. Oncol. 32, 443-451 (2005
114. Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nature Rev. Cancer 10, 457-469 (2010
115. Cao, Q. et al. Repression of E cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274-7284 (2008
116. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2 activating mutations. Nature 492, 108-112 (2012
117. Tam, W. L. & Weinberg, R. A. The epigenetics of epithelial- mesenchymal plasticity in cancer. Nature Med. 19, 1438-1449 (2013
118. Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL AF9. Nature 442, 818-822 (2006
119. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011
120. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011
121. Bhola, N. E. et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348-1358 (2013
122. Ocana, O. H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709-724 (2012
123. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012
124. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012
125. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
126. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA 4 blockade. Science 271, 1734-1736 (1996
127. Yoshimura, A. & Muto, G. TGF-β function in immune suppression. Curr. Top. Microbiol. Immunol. 350, 127-147 (2011
128. Wan, Y. Y. & Flavell, R. A. 'Yin-Yang' functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol. Rev. 220, 199-213 (2007
129. Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519-530 (1927
130. Tennant, D. A., Duran, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nature Rev. Cancer 10, 267-277 (2010
131. Elstrom, R. L. et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892-3899 (2004
132. Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007
133. Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008
134. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008
135. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009
136. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009
137. Gross, S. et al. Cancer-Associated metabolite 2 hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344 (2010
138. Ward, P. S. et al. The common feature of leukemia-Associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2 hydroxyglutarate. Cancer Cell 17, 225-234 (2010
139. Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Rev. Cancer 8, 851-864 (2008
140. Cannito, S. et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29, 2267-2278 (2008
141. Li, Z. & Rich, J. N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol. 345, 21-30 (2010
142. Dong, C. et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23, 316-331 (2013
143. Ginestier, C. et al. Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 30, 1327-1337 (2012
144. Rangarajan, A. & Weinberg, R. A. Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nature Rev. Cancer 3, 952-959 (2003
145. Hiramatsu, H. et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood 102, 873-880 (2003
146. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994
147. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737 (1997
148. Bapat, S. A., Mali, A. M., Koppikar, C. B. & Kurrey, N. K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65, 3025-3029 (2005
149. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158-10163 (2007
150. Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2007
151. O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110 (2007
152. Yang, Z. F. et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13, 153-166 (2008
153. Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007
154. Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593-598 (2008
155. Deshpande, A. J. et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/ AF10 positive leukemia. Cancer Cell 10, 363-374 (2006
156. Cho, R. W. et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt 1 murine breast tumors. Stem Cells 26, 364-371 (2008
157. Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature 488, 527-530 (2012
158. Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (2007
159. Schepers, A. G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730-735 (2012
160. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nature Rev. Immunol. 6, 295-307 (2006
161. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Rev. Immunol. 12, 269-281 (2012
162. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4, 71-78 (2004
163. DeNardo, D. G. et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102 (2009
164. Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257-272 (2011
165. Dirat, B. et al. Cancer-Associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455-2465 (2011
166. Butler, J. M., Kobayashi, H. & Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nature Rev. Cancer 10, 138-146 (2010
167. Civin, C. I. et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen Defined by a monoclonal antibody raised against KG 1a cells. J. Immunol. 133, 157-165 (1984
168. Andrews, R. G., Singer, J. W. & Bernstein, I. D. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J. Exp. Med. 169, 1721-1731 (1989
169. Lin, G., Finger, E. & Gutierrez-Ramos, J. C. Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues. Eur. J. Immunol. 25, 1508-1516 (1995
170. Healy, L. et al. The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc. Natl Acad. Sci. USA 92, 12240-12244 (1995
171. Ferrero, E. & Malavasi, F. The metamorphosis of a molecule: From soluble enzyme to the leukocyte receptor CD38. J. Leukoc. Biol. 65, 151-161 (1999
172. Borland, G., Ross, J. A. & Guy, K. Forms and functions of CD44. Immunology 93, 139-148 (1998
173. Ponta, H., Sherman, L. & Herrlich, P. A. CD44: From adhesion molecules to signalling regulators. Nature Rev. Mol. Cell Biol. 4, 33-45 (2003
174. Takaishi, S. et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006-1020 (2009
175. Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973-978 (2007
176. Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037 (2007
177. Kristiansen, G., Sammar, M. & Altevogt, P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J. Mol. Histol 35, 255-262 (2004
178. Zhang, C., Li, C., He, F., Cai, Y. & Yang, H. Identification of CD44+CD24+ gastric cancer stem cells. J. Cancer Res. Clin. Oncol. 137, 1679-1686 (2011
179. McKenzie, J. L. & Fabre, J. W. Human thy 1: Unusual localization and possible functional significance in lymphoid tissues. J. Immunol. 126, 843-850 (1981
180. Mayani, H. & Lansdorp, P. M. Thy 1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 83, 2410-2417 (1994
181. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006
182. Wetzel, A. et al. Human Thy 1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac 1 (CD11b/CD18).J. Immunol. 172, 3850-3859 (2004
183. Avalos, A. M., Labra, C. V., Quest, A. F. & Leyton, L. Signaling triggered by Thy 1 interaction with beta 3 integrin on astrocytes is an essential step towards unraveling neuronal Thy 1 function. Biol. Res. 35, 231-238 (2002
184. Rege, T. A. & Hagood, J. S. Thy 1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim. Biophys. Acta 1763, 991-999 (2006
185. Kroczek, R. A., Gunter, K. C., Germain, R. N. & Shevach, E. M. Thy 1 functions as a signal transduction molecule in T lymphocytes and transfected B lymphocytes. Nature 322, 181-184 (1986
186. He, J. et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol. Cell. Proteomics 11, M111.010744 (2012
187. Yang, Z. F. et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47, 919-928 (2008
188. Donnenberg, V. S., Landreneau, R. J. & Donnenberg, A. D. Tumorigenic stem and progenitor cells: Implications for the therapeutic index of anti-cancer agents. J. Control Release 122, 385-391 (2007
189. Buhring, H. J. et al. Expression of novel surface antigens on early hematopoietic cells. Ann. NY Acad. Sci. 872, 25-38; discussion 38-39 (1999
190. Gehling, U. M. et al. In vitro differentiation of endothelial cells from AC133 positive progenitor cells. Blood 95, 3106-3112 (2000
191. Uchida, N. et al. Direct isolation of human central nervous system stem cells. Proc. Natl Acad. Sci. USA 97, 14720-14725 (2000
192. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004
193. Rutella, S. et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin. Cancer Res. 15, 4299-4311 (2009
194. Ma, S. et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132, 2542-2556 (2007
195. Bertolini, G. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA 106, 16281-16286 (2009
196. Ferrandina, G. et al. Expression of CD133 1 and CD133 2 in ovarian cancer. Int. J. Gynecol. Cancer 18, 506-514 (2008
197. Deng, S. et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 5, e10277 (2010
198. Marchitti, S. A., Brocker, C., Stagos, D. & Vasiliou, V. Non P450 aldehyde oxidizing enzymes: The aldehyde dehydrogenase superfamily. Expert Opin. Drug Metab. Toxicol. 4, 697-720 (2008
199. Black, W. & Vasiliou, V. The aldehyde dehydrogenase gene superfamily resource center. Hum. Genom. 4, 136-142 (2009
200. Huang, E. H. et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation During colon tumorigenesis. Cancer Res. 69, 3382-3389 (2009
201. Chen, Y. C. et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem. Biophys. Res. Commun. 385, 307-313 (2009
202. Boonyaratanakornkit, J. B. et al. Selection of tumorigenic melanoma cells using ALDH. J. Invest. Dermatol. 130, 2799-2808 (2010
203. Alvi, A. J. et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5, R1-R8 (2003
204. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/ progenitor cells. Genes Dev. 17, 1253-1270 (2003
205. Majka, S. M. et al. Identification of novel resident pulmonary stem cells: Form and function of the lung side population. Stem Cells 23, 1073-1081 (2005
206. Martin, C. M. et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev. Biol. 265, 262-275 (2004
207. Hussain, S. Z. et al. Side population cells derived from adult human liver generate hepatocyte-like cells in vitro. Dig. Dis. Sci. 50, 1755-1763 (2005
208. Kim, M. & Morshead, C. M. Distinct populations of forebrain neural stem and progenitor cells can be isolated using side-population analysis. J. Neurosci. 23, 10703-10709 (2003
209. Larderet, G. et al. Human side population keratinocytes exhibit long-Term proliferative potential and a specific gene expression profile and can form a pluristratified epidermis. Stem Cells 24, 965-974 (2006
210. Chua, C. et al. Characterization of a side population of astrocytoma cells in response to temozolomide. J. Neurosurg. 109, 856-866 (2008
211. Haraguchi, N. et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24, 506-513 (2006
212. Bleau, A. M. et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235 (2009
213. Chiba, T. et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44, 240-251 (2006
214. Ho, M. M., Ng, A. V., Lam, S. & Hung, J. Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827-4833 (2007
215. Mitsutake, N. et al. Characterization of side population in thyroid cancer cell lines: Cancer stem-like cells are enriched partly but not exclusively. Endocrinology 148, 1797-1803 (2007
216. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2012
217. Yu, M. et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487, 510-513 (2012
218. Gonsalves, F. C. et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl Acad. Sci. USA 108, 5954-5963 (2011
219. Zhu, C. et al. Phosphosulindac (OXT 328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem Cells 30, 2065-2075 (2012
220. Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009
221. Garber, K. Drugging the Wnt pathway: Problems and progress. J. Natl Cancer Inst. 101, 548-550 (2009
222. Heidel, F. H. et al. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412-424 (2012
223. Yeung, J. et al. β-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606-618 (2010
224. Malanchi, I. et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 452, 650-653 (2008
225. Bueno, L. et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur. J. Cancer 44, 142-150 (2008
226. Anido, J. et al. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655-668 (2010
227. Kabashima, A. et al. Side population of pancreatic cancer cells predominates in TGF-β-mediated epithelial to mesenchymal transition and invasion. Int. J. Cancer 124, 2771-2779 (2009
228. Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243 (2011
229. Schlingensiepen, K. H. et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129-139 (2006
230. Olson, R. E. & Albright, C. F. Recent progress in the medicinal chemistry of γ-secretase inhibitors. Curr. Top. Med. Chem. 8, 17-33 (2008
231. Lanz, T. A. et al. Pharmacodynamics and pharmacokinetics of the γ-secretase inhibitor PF 3084014. J. Pharmacol. Exp. Ther. 334, 269-277 (2010
232. Richter, S. et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL 078/CTEP 8575).Invest. New Drugs 32, 243-249 (2013
233. Harrison, H. et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70, 709-718 (2010
234. McAuliffe, S. M. et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl Acad. Sci. USA 109, E2939-E2948 (2012
235. Zhu, T. S. et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 71, 6061-6072 (2011
236. Palagani, V. et al. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by gamma-secretase inhibitor IX. PLoS ONE 7, e46514 (2012
237. Jenkins, D. W. et al. MEDI0639: A novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol. Cancer Ther. 11, 1650-1660 (2012
238. Cooper, M. K., Porter, J. A., Young, K. E. & Beachy, P. A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280, 1603-1607 (1998
239. Robarge, K. D. et al. GDC 0449 - A potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19, 5576-5581 (2009
240. Buonamici, S. et al. Interfering with resistance to Smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2, 51ra70 (2010
241. Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I. & Ruiz i Altaba, A. HEDGEHOG GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17, 165-172 (2007
242. Bar, E. E. et al. Cyclopamine-mediated Hedgehog pathway inhibition Depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524-2533 (2007
243. Feldmann, G. et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196 (2007
244. Dierks, C. et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238-249 (2008
245. Peacock, C. D. et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl Acad. Sci. USA 104, 4048-4053 (2007
246. Wallner, L. et al. Inhibition of interleukin 6 with CNTO328, an anti-interleukin 6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 66, 3087-3095 (2006
247. Nakashima, Y. et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: Tocilizumab in combination with methotrexate. Mod. Rheumatol 20, 343-352 (2010
248. Sherry, M. M., Reeves, A., Wu, J. K. & Cochran, B. H. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27, 2383-2392 (2009
249. Lin, L. et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71, 7226-7237 (2011
250. Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009
251. Kroon, P. et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 73, 5288-5298 (2013
252. Song, H., Wang, R., Wang, S. & Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl Acad. Sci. USA 102, 4700-4705 (2005
253. Debnath, B., Xu, S. & Neamati, N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J. Med. Chem. 55, 6645-6668 (2012
254. Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771-15781 (1991
255. Nemunaitis, J. et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-Alpha, in patients with advanced cancer. J. Clin. Oncol. 17, 3586-3595 (1999